Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia

NCT07536269 is registered in ClinicalTrials.gov with Neurocrine Switzerland GmbH as lead sponsor.

NCT NCT07536269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07536269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia
Lead sponsor
Neurocrine Switzerland GmbH
Phase
Phase 2
Overall status
Recruiting
Start date
July 1, 2026
Completion date
March 31, 2028
Enrollment
20 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

congenital adrenal hyperplasia